Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFox Chase Cancer Center
About this trial
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
The main questions the study aims to answer are:
* Can ART improve how well radiation therapy targets the most aggressive cancer cells, while protecting the healthy tissue around the tumor? * Can ART help reduce the side effects that participants may experience during treatment?
Participants will:
* Undergo CT scans to plan the exact location of the radiation treatment. During this process, 1-3 small markers may be placed in or near the tumor to help with the planning. * Have a tumor biopsy, which involves taking a small sample of tissue from the cancer. * Receive 5 radiation treatments every other day over a 2-week period. * Provide blood samples before, during, and after your radiation treatment.
Eligibility criteria
Qualifiers
Patients must have histologically or cytologically-confirmed PDA.
Patients must have locally advanced unresectable PDA.
Patients enrolled onto the dose escalation arm may have started chemotherapy prior to initiation of radiation therapy and the last dose of chemotherapy must occur at least 2 weeks before start of ART.
Eastern Cooperative Oncology Group, or ECOG, performance status 0-2.
Disqualifiers
Radiologically or cytologically confirmed metastatic disease.
Patients who have had any prior radiation therapy for pancreatic cancer.
Patients who have had prior chemoradiation to an overlapping volume.
Patients with adenosquamous carcinoma of the pancreas.
Trial design
Treatments tested in this trial
- Adaptive Radiation Therapy
Treatment groups
16 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov